Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4332

Sort by

Sort Order Select

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

BCR-ABL and Src Family Kinases Induce YAP Tyrosine Phosphorylation Resulting in Survivin and Cyclin D1 Expression in Chronic Myeloid Leukemia Cells

Toshiyuki Hori, MD PhD, Kenta Moriyama, MS

Blood (2019) 134 (Supplement_1): 5366.

https://doi.org/10.1182/blood-2019-124643

Published: 2019

Journal Articles

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD

Blood (2019) 134 (Supplement_1): 5369.

https://doi.org/10.1182/blood-2019-129768

Published: 2019

Journal Articles

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Monica Kasbekar, Valentina Nardi, MD, Paola Dal Cin, Andrew M. Brunner, MD, Yi-Bin Chen, Christine Connolly, Amir T. Fathi, MD, Julia Foster, ANP, Molly Macrae, Steven L McAfee, MD, Kristin McGregor, Rupa Narayan, Aura Y. Ramos, Tina T. Som, RN, Megan Vartanian, RN, Robb S Friedman, MD, Karim Benhadji, MD MSC, Gabriela S. Hobbs, MD

Blood (2019) 134 (Supplement_1): 5371.

https://doi.org/10.1182/blood-2019-124100

Published: 2019

Journal Articles

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Ekin Kircali, Guldane Cengiz Seval, Sinem Civriz Bozdag, MD, Selami Kocak Toprak, MD, Meltem Kurt Yuksel, MD, Onder Arslan, Muhit Özcan, Taner Demirer, MD, Gunhan Gurman, MD, Osman Ilhan, Hamdi Akan, MD, Meral Beksac, MD, Pervin Topcuoglu, MD

Blood (2019) 134 (Supplement_1): 4156.

https://doi.org/10.1182/blood-2019-127622

Published: 2019

Journal Articles

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Naoto Takahashi, MD PhD, Itaru Matsumura, MD PhD, Shin Fujisawa, MD, Kenichi Ishizawa, MD PhD, Takaaki ONO, MD PhD, Emiko Sakaida, MD PhD, Naohiro Sekiguchi, MD PhD, Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, Yuichiro Koide, Masayuki Hino, MD PhD

Blood (2019) 134 (Supplement_1): 4159.

https://doi.org/10.1182/blood-2019-121809

Published: 2019

Journal Articles

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Massimo Breccia, MD, Jorge E. Cortes, MD, Neil P Shah, MD PhD, Giuseppe Saglio, MD, Antonio Jiménez-Velasco, MD, Philipp Le Coutre, MD, Alexander Brun, PharmD, Irene DeGutis, Sai Bathena, Oumar Sy, PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 4155.

https://doi.org/10.1182/blood-2019-121872

Published: 2019

Journal Articles

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Tim H Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Camille Abboud, MD, Justin M. Watts, MD, Gianantonio Rosti, MD, Alexander Russell-Smith, Andrea Viqueira, MD, Arlene Reisman, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 4157.

https://doi.org/10.1182/blood-2019-124344

Published: 2019

Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD

Blood (2019) 134 (Supplement_1): 4160.

https://doi.org/10.1182/blood-2019-124710

Published: 2019

Journal Articles

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia-Single Center Retrospective Analysis

Seema Shrinivas Bhatwadekar, MDMDcine, Shubhangi Vishwas Deshpande, MD, Arpan Mehta, MD, Parth Shah, MD

Blood (2019) 134 (Supplement_1): 4162.

https://doi.org/10.1182/blood-2019-126495

Published: 2019

Journal Articles

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Pauline De Malglaive, MD, Matthieu Groh, MD, Guillaume Lefèvre, MD PhD, Chafika Morati Hafsaoui, MD, Magda Alexis, MD, Mathilde Hunault, MD PhD, Julien Seneschal, MD PhD, Hilaire Charlanne, MD, Claude Preudhomme, PharmD, PhD, Bernard Bonnotte, MD PhD, Jean Emmanuel Kahn, PhDMD

Blood (2019) 134 (Supplement_1): 2322.

https://doi.org/10.1182/blood-2019-131687

Published: 2019

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Yuya Sasaki, MD PhD, Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Rebecca Garris, MSc, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Michael E. Rytting, MD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P. Andrew Futreal, PhD, Feng Wang, PhD, Koichi Takahashi, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2753.

https://doi.org/10.1182/blood-2019-122017

Published: 2019

Journal Articles

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Blood (2019) 134 (Supplement_1): 2578.

https://doi.org/10.1182/blood-2019-125131

Published: 2019

Journal Articles

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Jeremy Chang, MD, Sherry Zhang, MD, Mojtaba Akhtari, MD

Blood (2019) 134 (Supplement_1): 2581.

https://doi.org/10.1182/blood-2019-123738

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Daigo Michimata, MD, Kazunori Murai, MD PhD, Yasuro Miyairi, MD, PhD, Yoshiaki Okano, MD, PhD, Yuuzou Suzuki, MD, PhD, Hiroyuki Hamada, MD, Akiyoshi Sato, MD, PhD, Tatsuo Oyake, Shugo Kowata, MD, PhD, Yasuhiko Tsukushi, MD, PhD, Norifumi Sugawara, MD, PhD, Akihiro Otsu, MD, PhD, Kenji Shimosegawa, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2019) 134 (Supplement_1): 2928.

https://doi.org/10.1182/blood-2019-125066

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

BCR-ABL and Src Family Kinases Induce YAP Tyrosine Phosphorylation Resulting in Survivin and Cyclin D1 Expression in Chronic Myeloid Leukemia Cells

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia-Single Center Retrospective Analysis

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only